You are here

New Drug Application Submitted to FDA for Single-Tablet HIV Regimen

Tenofovir-based treatment demonstrates high suppression rates

A new drug application (NDA) has been submitted to the FDA for an investigational, once-daily single tablet containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of human immunodeficiency virus-1 (HIV-1) infection in adults.

According to the product’s developer (Gilead Sciences), the data submitted in the NDA support the use of the regimen in adult and adolescent treatment-naïve HIV-infected individuals, in virologically suppressed patients who switch regimens, and in those with renal impairment. If approved, E/C/F/TAF would be the first single-tablet regimen to contain TAF.

TAF is an investigational prodrug of tenofovir, the active agent in Viread (tenofovir disoproxil fumarate, Gilead Sciences). TAF is a more targeted form of tenofovir than that found in Viread, and it has demonstrated high antiviral efficacy at a dose that is 10 times lower, as well as improved renal and bone safety profiles.

The NDA for E/C/F/TAF was supported by 48-week data from two pivotal phase III studies in which the regimen met its primary objective of non-inferiority compared with Stribild (elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg, and tenofovir disoproxil fumarate 300 mg, Gilead Sciences) in treatment-naïve HIV patients. In these studies, E/C/F/TAF demonstrated improved renal and bone safety compared with Stribild.

The NDA was also supported by data from additional phase III studies that evaluated the TAF-based regimen in virologically suppressed HIV patients who switched to E/C/F/TAF and in patients with renal impairment.

Source: Gilead Sciences; November 6, 2014.

Recent Headlines

Citrus, Berries, Broccoli Reduce Risk of Cancer and CVD
Changes in Antibiotic Recommendations for Children
Influences Gene Involved in Circadian Rhythms
‘The Perfect Drug for Trauma-Focused Psychotherapy’
Triggers the Body’s Own Natural Blood Flow Regulation
Inrebic Reduces Symptoms by 50% in Some Patients
Novel Catheter-based Technology for Treating Acute Ischemic Stroke
Decision supported by data from more than 4,000 patients